Biomarker for Traumatic Brain Injury and Neurointensive Care : Its Scientific Efficacy and Prospects

With the innovation of measuring techniques, research into several biomarker has been ongoing in neurocriti-cal care. In addition to the usual biomarkers such as neuron specific enolase, S100 β and glutamate, several new biomarkers along with their pathomechanisms have been studied in traumatic brain injury （ TBI ） patients. These biomarkers are neurofilament families derived from neural cytoskeleton, tau protein derived from dendritic micro-tubules, microtubule − associated protein 2 derived from dendritic cell body, myelin basic protein from oligodendro-cyte and myelin, ubiquitin C − terminal hydrolase − L1 derived from neural cells and glial fibrillary acidic protein from glial cells. these the efficacy of these biomarkers for the “ visualization ” of TBI pathophysiology.

[1]  Michael Y. Wang,et al.  Acute diagnostic biomarkers for spinal cord injury: review of the literature and preliminary research report. , 2015, World neurosurgery.

[2]  R. Bullock,et al.  Biomarkers for the Clinical Differential Diagnosis in Traumatic Brain Injury—A Systematic Review , 2013, CNS neuroscience & therapeutics.

[3]  A. Gabrielli,et al.  Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury , 2012, Brain injury.

[4]  P. D. Adelson,et al.  Increased CSF Concentrations of Myelin Basic Protein After TBI in Infants and Children: Absence of Significant Effect of Therapeutic Hypothermia , 2012, Neurocritical Care.

[5]  A. Gabrielli,et al.  Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. , 2012, Journal of neurotrauma.

[6]  S. Y. Chabok,et al.  Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury , 2012, The journal of trauma and acute care surgery.

[7]  R. Bullock,et al.  Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. , 2012, Journal of neurotrauma.

[8]  A. Gabrielli,et al.  Clinical Utility of Serum Levels of Ubiquitin C-terminal Hydrolase as a Biomarker for Severe Traumatic Brain Injury , 2022 .

[9]  F. Tortella,et al.  Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study , 2011, Critical care.

[10]  J. Žůrek,et al.  Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children , 2011, Brain injury.

[11]  B. Aarabi,et al.  Association of CSF Biomarkers and Secondary Insults Following Severe Traumatic Brain Injury , 2011, Neurocritical care.

[12]  H. Weng,et al.  Tau proteins in serum predict outcome after severe traumatic brain injury. , 2010, The Journal of surgical research.

[13]  R. Morochovič,et al.  Serum S100B protein in early management of patients after mild traumatic brain injury , 2009, European journal of neurology.

[14]  M. Sitzer,et al.  Characterisation of the Diagnostic Window of Serum Glial Fibrillary Acidic Protein for the Differentiation of Intracerebral Haemorrhage and Ischaemic Stroke , 2008, Cerebrovascular Diseases.

[15]  C. Lindsell,et al.  Serum cleaved tau does not predict postconcussion syndrome after mild traumatic brain injury. , 2008, The American journal of emergency medicine.

[16]  S. Beers,et al.  Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children. , 2007, Journal of neurotrauma.

[17]  K. Blennow,et al.  Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury , 2006, Neurology.

[18]  F. Tortella,et al.  Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury , 2006, Journal of neurochemistry.

[19]  P. Kochanek,et al.  Serum Biomarkers after Traumatic and Hypoxemic Brain Injuries: Insight into the Biochemical Response of the Pediatric Brain to Inflicted Brain Injury , 2006, Developmental Neuroscience.

[20]  P. Kochanek,et al.  Identification of Inflicted Traumatic Brain Injury in Well-Appearing Infants Using Serum and Cerebrospinal Markers: A Possible Screening Tool , 2006, Pediatrics.

[21]  K. Blennow,et al.  Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome , 2006, Journal of the Neurological Sciences.

[22]  A. Petzold.  Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss , 2005, Journal of the Neurological Sciences.

[23]  J. Langlois,et al.  The Public Health Approach to Traumatic Brain Injury: An Overview of CDC's Research and Programs , 2005, The Journal of head trauma rehabilitation.

[24]  J. Langlois,et al.  Tracking the Silent Epidemic and Educating the Public: CDC's Traumatic Brain Injury—Associated Activities Under the TBI Act of 1996 and the Children's Health Act of 2000 , 2005, The Journal of head trauma rehabilitation.

[25]  A. Raabe,et al.  GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. , 2004, Journal of neurotrauma.

[26]  A. Raabe,et al.  Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. , 2004, The Journal of trauma.

[27]  O. Tasaki,et al.  CHANGES IN CSF S100B AND CYTOKINE CONCENTRATIONS IN EARLY-PHASE SEVERE TRAUMATIC BRAIN INJURY , 2004, Shock.

[28]  T. Beems,et al.  Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury , 2004, Neurology.

[29]  M. Senac,et al.  Detection of traumatic brain injury with magnetic resonance imaging and S-100B protein in children, despite normal computed tomography of the brain* , 2003, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[30]  E. Jauch,et al.  C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome , 2002, Brain Research.

[31]  E. Jauch,et al.  Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. , 2002, Annals of emergency medicine.

[32]  A. Twijnstra,et al.  S‐100B and neuron‐specific enolase in serum of mild traumatic brain injury patients
A comparison with healthy controls , 2001, Acta neurologica Scandinavica.

[33]  Manfred Herrmann,et al.  Release of Glial Tissue–Specific Proteins After Acute Stroke: A Comparative Analysis of Serum Concentrations of Protein S-100B and Glial Fibrillary Acidic Protein , 2000, Stroke.

[34]  V. Seifert,et al.  Serum S-100B protein in severe head injury. , 2000, Neurosurgery.

[35]  C. Alling,et al.  Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. , 2000, The Annals of thoracic surgery.

[36]  A. Ebert,et al.  Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography. , 2000, Journal of neurotrauma.

[37]  J. Rafols,et al.  Disruption of MAP-2 immunostaining in rat hippocampus after traumatic brain injury. , 1998, Journal of neurotrauma.

[38]  D. Graham,et al.  Axonal cytoskeletal changes after non-disruptive axonal injury , 1997, Journal of neurocytology.

[39]  D. Zimmer,et al.  The S100 protein family: History, function, and expression , 1995, Brain Research Bulletin.

[40]  T. Ohwada,et al.  Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. , 1995, Surgical neurology.

[41]  H. Murofushi.  [Microtubule-associated proteins]. , 1993, Seikagaku. The Journal of Japanese Biochemical Society.

[42]  A. Matus,et al.  Selective localization of messenger RNA for cytoskeletal protein MAP2 in dendrites , 1988, Nature.

[43]  D. Thomas,et al.  SERUM-MYELIN-BASIC-PROTEIN ASSAY IN DIAGNOSIS AND PROGNOSIS OF PATIENTS WITH HEAD INJURY , 1978, The Lancet.

[44]  O. Benada,et al.  Immunohistochemistry and serum values of S-100B, glial fibrillary acidic protein, and hyperphosphorylated neurofilaments in brain injuries. , 2012, Soudni lekarstvi.

[45]  J. Žůrek,et al.  The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury , 2011, Acta Neurochirurgica.

[46]  R. Vink,et al.  Multifunctional drugs for head injury , 2011, Neurotherapeutics.

[47]  J. Ghajar,et al.  In Reply: Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations. , 2020, Neurosurgery.

[48]  M. Wiesmann,et al.  Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. , 1999, Clinical chemistry.

[49]  V. Seifert,et al.  Correlation of Computed Tomography Findings and Serum Brain Damage Markers Following Severe Head Injury , 1998, Acta Neurochirurgica.